

## Eleven Biotherapeutics

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 07-Dec-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Discovery..... 14

[Return to Table of Contents](#)

# Eleven Biotherapeutics

## COMPANY OVERVIEW

Company Name	Eleven Biotherapeutics
Parent Company Name	Eleven Biotherapeutics
Website	http://www.elevenbio.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	5
Number of Patents as Owner	12
Number of Patents as Third Party	2
Number of Deals	2
Key Indications	Xerophthalmia, Diabetic macular edema, Inflammatory disease, Allergy, Diabetic eye disease, Autoimmune disease, Ocular disease, Allergic conjunctivitis, Cancer, Rheumatoid arthritis
Key Target-based Actions	IL-1 antagonist, IL-17 antagonist, Type I IL-1 receptor antagonist, IL-6 antagonist, Interleukin-6 ligand inhibitor, Factor VIII agonist, GDF-8 antagonist, Interleukin-1 ligand modulator, Albumin agonist, IL-23 antagonist, Interleukin-1 beta ligand inhibitor, Interleukin-1 beta ligand modulator, Type I IL-1 receptor modulator
Key Technologies	Biological therapeutic, Peptide, Parenteral formulation unspecified, Ophthalmic formulation, Antibody, Injectable formulation, Protein chimeric, Dermatological formulation, Local formulation unspecified, Transdermal formulation

## COMPANY PROFILE

### SUMMARY

Eleven Biotherapeutics aims to develop protein-based therapeutics, with an initial focus on inflammatory conditions and coagulation disorders.

### FINANCIAL

In November 2014, the company entered into an agreement for the sale of 1,743,680 shares of its common stock at \$11.47 per share and warrants to purchase approximately 871,840 shares of common stock at a price of \$15 per share. The gross proceeds were expected to be \$20 million. At that time, the transaction was expected to be closed on December 1, 2014 and the warrants would expire in three years from the date of issuance.

March 2014, the company was added to the Russell 2000 and Russell 3000 Indexes.

In January 2014, the company filed a registration statement on Form S-1 for a proposed initial public offering of shares of its common stock. In February 2014, the company priced the offering of 5 million common stock shares at a price of \$10 each. The underwriters were granted a 30-day option to buy up to 750,000 additional shares of common stock to cover over-allotments, at the public offering price less the underwriting discount. Eleven's common stock began trading on the NASDAQ Global Market under the ticker symbol 'EBIO'. Later that month, the company closed the IPO and issued 5,750,000 common stock shares including 750,000 shares of common stock upon full exercise by the underwriters. By May 2014, the company raised net proceeds of approximately \$50.2 million from the initial public offering.

In May 2012, the company secured \$20 million in a series A equity financing, expanding the total amount raised to \$45 million.

In February 2010, Eleven raised \$35 million in a series A financing.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Immune disorder	1	3	4
Inflammatory disease	1	3	4
Ocular disease	3	0	3
Musculoskeletal disease	0	2	2
Hematological disease	0	2	2
Dermatological disease	0	1	1
Growth disorder	0	1	1
Metabolic disorder	0	1	1
Cardiovascular disease	1	0	1
Genetic disorder	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	3
No Development Reported	5

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	0	0	1
Drug - Funding	1	0	0	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	1	4
Inflammatory disease	0	2

[Return to Table of Contents](#)

## Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	0	2
Phase 1	0	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	1	1	2
Gastrointestinal disease	3	1	4
Genitourinary disease	0	1	1
Hematological disease	1	0	1
Degeneration	1	0	1
Immune disorder	5	1	6
Musculoskeletal disease	3	0	3
Neoplasm	1	2	3
Ocular disease	6	0	6
Metabolic disorder	2	0	2
Neurological disease	4	0	4
Respiratory disease	0	1	1
Infectious disease	1	1	2
Inflammatory disease	8	0	8
Gynecology and obstetrics	0	1	1

[Return to Table of Contents](#)





Dermatological disease	1	1	2
------------------------	---	---	---

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### EBI-005

#### EBI-005 SNAPSHOT

<b>Drug Name</b>	EBI-005
<b>Key Synonyms</b>	
<b>Originator Company</b>	Eleven Biotherapeutics
<b>Active Companies</b>	Eleven Biotherapeutics
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Xerophthalmia;Allergy
<b>Target-based Actions</b>	IL-1 antagonist;Type I IL-1 receptor antagonist
<b>Other Actions</b>	Ophthalmological agent
<b>Technologies</b>	Ophthalmic formulation;Biological therapeutic;Peptide;Protein chimeric
<b>Last Change Date</b>	14-Nov-2014

#### EBI-005 DEVELOPMENT PROFILE

##### SUMMARY

Eleven Biotherapeutics is developing the protein therapeutic EBI-005 (EBI-005-2), an IL-1 antagonist, developed using its protein engineering platform, AMP-Rx, for the potential topical ophthalmic treatment of dry eye and ocular allergy including allergic conjunctivitis. In February 2014, phase III trial for dry eye disease was initiated ; in November 2014, top-line results were expected in the second quarter of 2015. In August 2014, a second pivotal, 12-month safety trial was expected to be initiated later that year. At that time, the company planned filing a BLA with the US FDA for dry eye disease in the second half of 2016. In March 2014, a phase II trial was initiated in Canada ; in October 2014, topline data were reported.

#### EBI-005 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Eleven Biotherapeutics	Xerophthalmia	US	Phase 3 Clinical	18-Feb-2014
Eleven Biotherapeutics	Allergy	Canada	Phase 2 Clinical	04-Mar-2014
Eleven Biotherapeutics	Allergy	US	Phase 1 Clinical	22-Nov-2012

[Return to Table of Contents](#)



## EBI-005 DRUG NAMES

Names	Type
EBI-005-2	Research Code
EBI-005	Research Code
IL-1 antagonist (ocular diseases), Eleven Biotherapeutics	

## EBI-005 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Xerophthalmia											
0	0	1	1	0	0	0	1	0	0	1	2
Allergic conjunctivitis											
0	0	0	0	0	2	0	0	0	0	0	2

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	0	2	0	2	0	0	1	5

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Eleven Biotherapeutics	3	0	3
Northeastern University	0	1	1
ChromaTan Corporation	0	1	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	2
Product	1

## EBI-028

### EBI-028 SNAPSHOT

Drug Name	EBI-028
Key Synonyms	
Originator Company	Eleven Biotherapeutics
Active Companies	Eleven Biotherapeutics
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease
Target-based Actions	IL-17 antagonist
Other Actions	Topical antipsoriatic product;Anti-inflammatory
Technologies	Injectable formulation;Dermatological formulation;Ophthalmic formulation;Biological therapeutic;Parenteral formulation unspecified;Peptide
Last Change Date	16-May-2014

### EBI-028 DEVELOPMENT PROFILE

#### SUMMARY

Eleven Biotherapeutics is investigating EBI-028, a protein therapeutic, that inhibits IL-17 receptor and also blocks multiple IL-17 ligands, for the potential intravitreal treatment of inflammatory diseases including uveitis. In January 2012, the program was listed as being in preclinical development ; in January 2014, this was still the case.

The company was previously investigating the program as EBI-006, for the potential topical treatment of inflammatory diseases including uveitis. In January 2012, the program was listed as being in preclinical development . However, in January 2014, the research code was no longer listed on the company's pipeline.

The company was previously investigating the program, for the potential treatment of psoriasis and autoimmune diseases. In January 2012, the program was listed as being in preclinical development ; however, in November 2012, the indications were no longer listed on the company's pipeline as under development.

### EBI-028 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Eleven Biotherapeutics	Inflammatory disease	US	Discovery	16-Jan-2012
Eleven Biotherapeutics	Autoimmune disease	US	No Development Reported	22-Nov-2012

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
Eleven Biotherapeutics	Psoriasis	US	No Development Reported	22-Nov-2012

## EBI-028 DRUG NAMES


Names	Type
IL-17 receptor/ligand antagonist (psoriasis/autoimmune disease/inflammatory disease), Eleven Biotherapeutics EBI-028	Research Code
EBI-006	Research Code

## EBI-028 DEALS AND PATENTS

### PATENTS

#### Patents by Parent Company Chart

Chart displayed by Owner/Third Party




#### Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Eleven Biotherapeutics	3	0	3
Stanford University	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1
Formulation	1
Component of Combination	1
Product	1

[Return to Table of Contents](#)



## eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics

### eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics SNAPSHOT

<b>Drug Name</b>	eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics
<b>Key Synonyms</b>	
<b>Originator Company</b>	ThromboGenics NV
<b>Active Companies</b>	Eleven Biotherapeutics;ThromboGenics NV
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Diabetic eye disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	Ophthalmological agent;Unspecified drug target
<b>Technologies</b>	Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
<b>Last Change Date</b>	10-Oct-2014

### eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics DEVELOPMENT PROFILE

#### SUMMARY

ThromboGenics, in collaboration with Eleven Biotherapeutics, is investigating recombinant protein therapeutics by using AMP-Rx protein design technology of Eleven for the potential treatment of diabetic eye disease including diabetic macular edema. In May 2013, the drug was listed as being in preclinical development. In August 2014, the program was listed as being in proof-of-concept studies and at that time, the company was planning to initiate preclinical trials.

### eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Eleven Biotherapeutics	Diabetic eye disease	US	Discovery	28-May-2013
ThromboGenics NV	Diabetic eye disease	Belgium	Discovery	28-May-2013

### eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics DRUG NAMES


Names	Type
eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics	

[Return to Table of Contents](#)

eleven program (recombinant protein therapeutics, diabetic eye disease), Eleven Biotherapeutics/ThromboGenics DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
ThromboGenics NV	0	0	1	0	1
Eleven Biotherapeutics	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

## EBI-031

### EBI-031 SNAPSHOT

Drug Name	EBI-031
Key Synonyms	
Originator Company	Eleven Biotherapeutics
Active Companies	Eleven Biotherapeutics
Inactive Companies	
Highest Status	Discovery
Active Indications	Diabetic macular edema
Target-based Actions	IL-6 antagonist;Interleukin-6 ligand inhibitor
Other Actions	Anti-inflammatory
Technologies	Antibody;Injectable formulation;Ophthalmic formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	26-Nov-2014

### EBI-031 DEVELOPMENT PROFILE

#### SUMMARY

Eleven Biotherapeutics is investigating EBI-031, an antibody that targets IL-6, for the potential intravitreal treatment of eye diseases including diabetic macular edema and uveitis. In November 2014, the company was planning for clinical trials.

The company was previously investigating the program as EBI-029. In January 2014, the program was listed as being in preclinical development. In May 2014, an IND filing was expected in the first half of 2015. However, by November 2014, the research code was no longer listed on the company's pipeline.

The company was previously investigating the program as EBI-018. In November 2012, the research code was listed as being in preclinical development. However, by January 2014, the research code was no longer listed on the company's pipeline.

The company was previously investigating EBI-007, an antibody that targets against IL-6 ligand, for the potential treatment of autoimmune and inflammatory diseases. In January 2012, the program was listed as being in preclinical development ; however, in November 2012, the program was no longer listed on the company's pipeline as under development.

### EBI-031 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Eleven Biotherapeutics	Diabetic macular edema	US	Discovery	22-Nov-2012

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Eleven Biotherapeutics	Autoimmune disease	US	No Development Reported	22-Nov-2012
Eleven Biotherapeutics	Inflammatory disease	US	No Development Reported	22-Nov-2012

## EBI-031 DRUG NAMES


Names	Type
EBI-007	Research Code
EBI-018	Research Code
EBI-029	Research Code
IL-6 ligand inhibitor (antibody, autoimmune/inflammatory disease), Eleven Biotherapeutics	
EBI-031	Research Code

## EBI-031 DEALS AND PATENTS

### PATENTS

#### Patents by Parent Company Chart

Chart displayed by Owner/Third Party




#### Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Eleven Biotherapeutics	2	0	2

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1
Product	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

